12:00 AM
 | 
Oct 29, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ryzodeg insulin degludec/insulin aspart regulatory update

FDA is concerned about the cardiovascular safety of 2 Novo Nordisk insulin products under review for Type I and II diabetes, according to a document made public ahead of the Nov. 8 meeting of the Endocrinologic and Metabolic Drugs Advisory Committee to discuss NDAs for the products....

Read the full 214 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >